Letter: contraindicated drug‐drug interactions before and after initiation of direct‐acting anti‐viral agents in chronic hepatitis C patients in Taiwan
暂无分享,去创建一个
R. Chien | E. Lai | Kai-Cheng Chang | Y. Chan | S. Shao | Hui-yu Chen
[1] Y. Kao Yang,et al. The Chang Gung Research Database—A multi‐institutional electronic medical records database for real‐world epidemiological studies in Taiwan , 2019, Pharmacoepidemiology and drug safety.
[2] J. Kao,et al. Comorbidities, concomitant medications and potential drug‐drug interactions with interferon‐free direct‐acting antiviral agents in hepatitis C patients in Taiwan , 2018, Alimentary pharmacology & therapeutics.
[3] V. Sautou,et al. Managing drug–drug interactions with new direct‐acting antiviral agents in chronic hepatitis C , 2017, British journal of clinical pharmacology.
[4] S. Zeuzem,et al. The efficacy and safety of direct acting antiviral treatment and clinical significance of drug–drug interactions in elderly patients with chronic hepatitis C virus infection , 2016, Alimentary pharmacology & therapeutics.
[5] M. Charlton,et al. A clinician's guide to drug‐drug interactions with direct‐acting antiviral agents for the treatment of hepatitis C viral infection , 2016, Hepatology.
[6] H. Wedemeyer,et al. The clinical significance of drug–drug interactions in the era of direct‐acting anti‐viral agents against chronic hepatitis C , 2013, Alimentary pharmacology & therapeutics.
[7] E. Soffer,et al. Manometric tests of anorectal function in healthy adults , 1999, American Journal of Gastroenterology.